Tirzepatide
A Study to Evaluate ALN-2232 in Participants With Obesity
Eli Lilly · Phase 1/2 · Recruiting · Enrollment 156
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Part A: ALN-2232 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part A: Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part B: ALN-2232 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part B: Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part C: ALN-2232 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part C: Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part C: Tirzepatide | Obesity or overweight | n/r | n/r | n/r | n/r |